Reversal of gamma-radiation-induced leukemogenesis in mice by immunomodulation with thiabendazole and dinitrofluorobenzene.
The effect of thiabendazole (TBZ) and dinitrofluorobenzene (DNFB) on radiation-induced leukemogenesis was investigated in the C57BL/6 mouse model. Administration of TBZ-DNFB during, post, or during and post irradiation successfully blocked leukemogenesis, as indicated by the absence of leukemia blast cells in thymus and peripheral blood, as well as prevented thymic lymphoma. TBZ-DNFB treatment prevented the development of leukemia when studies were terminated both after 7 months of last irradiation (disease fully developed) and after 5 months of last irradiation (disease in the process of development). This TBZ-DNFB treatment also resulted in a significant increase in survival.
D000818:Animals; D004139:Dinitrofluorobenzene / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005720:Gamma Rays; D007167:Immunotherapy; D007953:Leukemia, Radiation-Induced / Q000139:chemically induced* / Q000276:immunology / Q000517:prevention & control; D008136:Longevity / Q000187:drug effects; D008223:Lymphoma / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009578:Nitrobenzenes / Q000008:administration & dosage*; D009929:Organ Size / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000528:radiation effects; D013827:Thiabendazole / Q000008:administration & dosage* / Q000627:therapeutic use; D013950:Thymus Gland / Q000187:drug effects
D009578:Nitrobenzenes; D004139:Dinitrofluorobenzene; D013827:Thiabendazole